According to Akebia Therapeutics's latest financial reports the company's current revenue (TTM) is $0.19 B. In 2022 the company made a revenue of $0.29 B an increase over the years 2021 revenue that were of $0.21 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.19 B | -33.3% |
2022 | $0.29 B | 36.7% |
2021 | $0.21 B | -27.68% |
2020 | $0.29 B | -11.85% |
2019 | $0.33 B | 61.26% |
2018 | $0.20 B | 16.72% |
2017 | $0.17 B | 11495.05% |
2016 | $1.53 M | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 47,666.05% | ๐บ๐ธ USA |
Novartis NVS | $51.01 B | 26,094.25% | ๐จ๐ญ Switzerland |
Amgen AMGN | $28.19 B | 14,375.34% | ๐บ๐ธ USA |
Nektar Therapeutics
NKTR | $90.12 M | -53.72% | ๐บ๐ธ USA |